1. Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

3. Advanced Hormone-Sensitive Prostate Cancer

4. Combination Therapy

5. ADT + Chemotherapy CHAARTED Trial

6. Early Abiraterone in Newly Diagnosed mHNPC STAMPEDE Trial

7. Early Abiraterone in Newly Diagnosed mHNPC LATITUDE Trial

8. Selected Therapy-Related Adverse Events

9. ARASENS: Phase 3 Trial of Darolutamide (ODM-201) in mHSPC

10. Some New Approaches in Hormone-Sensitive Disease

11. Challenges in Deciding Therapy in Patients With mHSPC

12. Bone-Targeted Therapy in Metastatic Prostate Cancer

13. mCRPC With Bone Metastases

14. Treatment Options in mCRPC

15. Radium-223

16. ALSYMPCA: Randomized, Phase 3 Trial of Radium-223 in Symptomatic mCRPC

17. ERA 223: Phase 3 Radium-223 + Abiraterone and Prednisone in Chemo-Naïve mCRPC

18. Combination of Bone-Targeted Agents

19. OS in ALSYMPCA According to Bisphosphonate Use

20. 5 FDA-Approved Therapies Can Be Used in Any Sequence

21. Tumor Genetic Sequencing

22. Pembrolizumab in mCRPC KEYNOTE-199

23. PARP Inhibitors in the Treatment of Prostate Cancer

24. Germline Genetic Testing

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)